Adenocarcinoma - Pipeline Review, H1 2013

Description: Adenocarcinoma – Pipeline Review, H1 2013

Summary

Global Markets Direct's, 'Adenocarcinoma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Adenocarcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adenocarcinoma. Adenocarcinoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Adenocarcinoma.
- A review of the Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Adenocarcinoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Adenocarcinoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Adenocarcinoma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Adenocarcinoma 9
Adenocarcinoma Therapeutics under Development by Companies 11
Adenocarcinoma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 18
Comparative Analysis 18
Sanofi-Aventis, H1 2013 32
Gilead Sciences, Inc., H1 2013 33
Delcath Systems, Inc., H1 2013 34
Novartis AG, H1 2013 35
Astellas Pharma Inc., H1 2013 36
Aduro BioTech, H1 2013 37
Merck KGaA, H1 2013 38
Celldex Therapeutics, Inc., H1 2013 39
Lorus Therapeutics Inc, H1 2013 40
Peregrine Pharmaceuticals, Inc., H1 2013 41
Threshold Pharmaceuticals, Inc., H1 2013 42
GANYMED Pharmaceuticals AG, H1 2013 43
MacroGenics, Inc., H1 2013 44
BioCancell Therapeutics, Inc., H1 2013 45
Kinex Pharmaceuticals, LLC, H1 2013 46
Eleison Pharmaceuticals, Inc., H1 2013 47
Laboratorio Elea S.A.C.I.F. and A, H1 2013 48
Assessment by Monotherapy Products, H1 2013 49
Assessment by Combination Products, H1 2013 50
Assessment by Stage and Route of Administration, H1 2013 52
Assessment by Stage and Molecule Type, H1 2013 55
Adenocarcinoma Therapeutics – Drug Profile Updates 146
Adenocarcinoma Therapeutics – Discontinued Products 161
Adenocarcinoma Therapeutics – Discontinued Products (Contd..1) 162
Adenocarcinoma Therapeutics – Dormant Products 163
Adenocarcinoma Therapeutics – Dormant Products (Contd..1) 164
Adenocarcinoma Therapeutics – Dormant Products (Contd..2) 165
Adenocarcinoma Therapeutics – Dormant Products (Contd..3) 166
Adenocarcinoma Therapeutics – Dormant Products (Contd..4) 167
Adenocarcinoma Therapeutics – Dormant Products (Contd..5) 168

List of Figures
Number of Products under Development for Adenocarcinoma, H1 2013 13
Products under Development for Adenocarcinoma – Comparative Analysis, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 18
Late Stage Products, H1 2013 22
Mid Clinical Stage Products, H1 2013 23
Early Clinical Stage Products, H1 2013 24
Pre-Clinical Stage Products, H1 2013 25
Assessment by Monotherapy Products, H1 2013 49
Assessment by Combination Products, H1 2013 50
Assessment by Route of Administration, H1 2013 51
Assessment by Stage and Route of Administration, H1 2013 52
Assessment by Molecule Type, H1 2013 53
Assessment by Stage and Molecule Type, H1 2013 54

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2497211/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Adenocarcinoma - Pipeline Review, H1 2013
Web Address: http://www.researchandmarkets.com/reports/2497211/
Office Code: SCD23GS1

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: *
Job Title: __________________________________________
Organisation: ________________________________________
Address: ___________________________________________
City: ______________________________________________
Postal / Zip Code: ___________________________________
Country: ___________________________________________
Phone Number: _______________________________________
Fax Number: _______________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World